Advances in the Diagnosis and Treatment of Neuroblastoma

Advances in the Diagnosis and Treatment of Neuroblastoma Joanna L. Weinstein, Howard M. Katzenstein, Susan L. Cohn Oncologist 2003; 8: 278-292 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Appreciate the heterogeneity of neuroblastoma and identify clinical and biological prognostic factors. Understand the determinants and the clinical significance of the neuroblastoma risk stratification system. Be able to select appropriate treatment regimens for neuroblastoma patients that are tailored according to risk stratification. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 23, 2003 Most Recent Review: May 23, 2003* Most Recent Update: May 23, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.